CSIMarket
 


Pliant Therapeutics Inc   (PLRX)
Other Ticker:  
 
 

PLRX's Income from Cont. Operations Growth by Quarter and Year

Pliant Therapeutics Inc 's Income from Cont. Operations results by quarter and year




PLRX Income from Cont. Operations (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December - -35.06 -24.53 33.54
III Quarter September -41.49 -30.62 -27.05 -16.53
II Quarter June -41.19 -29.55 -22.83 -17.00
I Quarter March -37.55 -28.10 -22.86 0.00
FY   -120.23 -123.33 -97.27 0.01



PLRX Income from Cont. Operations third quarter 2023 Y/Y Growth Comment
Pliant Therapeutics Inc in the third quarter 2023 recorded loss from continued operations of $ -41.49 millions.

According to the results reported in the third quarter 2023, Pliant Therapeutics Inc achieved the best Income from Cont. Operations growth in Major Pharmaceutical Preparations industry. While Pliant Therapeutics Inc ' s Income from Cont. Operations no change of % ranks overall at the positon no. in the third quarter 2023.




PLRX Income from Cont. Operations ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Pliant Therapeutics Inc 's third quarter 2023 Income from Cont. Operations $ -41.49 millions PLRX's Income Statement
Pliant Therapeutics Inc 's third quarter 2022 Income from Cont. Operations $ -30.62 millions Quarterly PLRX's Income Statement
New: More PLRX's historic Income from Cont. Operations Growth >>


PLRX Income from Cont. Operations (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




Income from Cont. Operations third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Income from Cont. Operations third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Income from Cont. Operations by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Pliant Therapeutics Inc 's Q/Q Income from Cont. Operations Growth


Income from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


PLRX's III. Quarter Q/Q Income from Cont. Operations Comment
Recent accomplishment of -41.49 millions by Pliant Therapeutics Inc look even more unfavourable if you take a look at -41.19 millions in the previous quarter.

Within Major Pharmaceutical Preparations industry Pliant Therapeutics Inc achieved highest sequential Income from Cont. Operations growth. While Pliant Therapeutics Inc 's Income from Cont. Operations growth quarter on quarter, overall rank is .


Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


PLRX's III. Quarter Q/Q Income from Cont. Operations Comment
III. Quarter 2023 accomplishment of -41.49 millions by Pliant Therapeutics Inc appear even more unfavourable compare to the -41.19 millions loss from continued operations a quarter before.

Within Major Pharmaceutical Preparations industry Pliant Therapeutics Inc achieved highest sequential Income from Cont. Operations growth. While Pliant Therapeutics Inc 's Income from Cont. Operations growth quarter on quarter, overall rank is .


Pliant Therapeutics Inc 's 12 Months Income from Cont. Operations Growth Year on Year


Income from Cont. Operations TTM Growth

12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
12 Months Ending
(Sep 30 2022)
Cumulative Income from Cont. Operations 12 Months Ending $ -155.29 $ -144.42 $ -132.77 $ -123.32 $ -112.79
Y / Y Income from Cont. Operations Growth (TTM) - - - - -
Year on Year Income from Cont. Operations Growth Overall Ranking # # # # #
Seqeuential Income from Cont. Operations Change (TTM) - - - - -
Seq. Income from Cont. Operations Growth (TTM) Overall Ranking # # # # #




Cumulative Income from Cont. Operations growth Comment
Pliant Therapeutics Inc ' has realized cumulative trailing twelve months loss from continued operations of $ -155 millions in the Sep 30 2023 period.
The business is detiriorating as the cumulative loss from continued operations is becoming larger from $ -144.42 millions in the twelve months ending a quarter before and $ -109.222 millions for the twelve months ending in the quarter a year ago Nara Ferreira mentioned.

Pliant Therapeutics Inc achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Income from Cont. Operations growth Comment
Pliant Therapeutics Inc ' has realized cumulative trailing twelve months loss from continued operations of $ -155 millions in the Sep 30 2023 period.
The situation is detiriorating as the cumulative loss from continued operations is becoming larger from $ -144.42 millions in TTM ending quarter Jun 30 2023 and $ -109.222 millions from the TTM period ending Sep 30 2022 Nara Ferreira told.

Pliant Therapeutics Inc achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Income from Cont. Operations Growth
Major Pharmaceutical Preparations Industry Income from Cont. Operations Growth Trends and Statistics
Healthcare Sector Income from Cont. Operations Growth Statistics
Income from Cont. Operations Growth Trends for overall market
PLRX's Income from Cont. Operations Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Income from Cont. Operations Growth
Lowest Ranking Income from Cont. Operations Growth
Income from Cont. Operations Growth for PLRX's Competitors
Income from Cont. Operations Growth for Pliant Therapeutics Inc 's Suppliers
Income from Cont. Operations Growth for PLRX's Customers

You may also want to know
PLRX's Annual Growth Rates PLRX's Profitability Ratios PLRX's Asset Turnover Ratio PLRX's Dividend Growth
PLRX's Roe PLRX's Valuation Ratios PLRX's Financial Strength Ratios PLRX's Dividend Payout Ratio
PLRX's Roa PLRX's Inventory Turnover Ratio PLRX's Growth Rates PLRX's Dividend Comparisons



Companies with similar Income from Cont. Operations no change for the quarter ending Sep 30 2023 within Healthcare SectorY/Y Change %Income from Cont. Operations for the quarter ending Sep 30 2023
Select Medical Holdings Corp59.51%$ 59.513 millions
Infusystem Holdings Inc55.53%$ 55.530 millions
Incyte Corporation51.87%$ 51.868 millions
Teva Pharmaceutical Industries Limited51.72%$ 51.724 millions
Semler Scientific Inc 50.04%$ 50.041 millions
Iradimed Corporation47.86%$ 47.856 millions
Merck and Co Inc 46.02%$ 46.019 millions
Lftd Partners Inc 45.85%$ 45.849 millions
Msa Safety Incorporated45.32%$ 45.317 millions
Option Care Health Inc 45.02%$ 45.022 millions
Ir med Inc 37.73%$ 37.734 millions
Lemaitre Vascular Inc 37.50%$ 37.500 millions
Becton Dickinson And Company36.61%$ 36.607 millions
Encompass Health Corporation34.15%$ 34.152 millions
West Pharmaceutical Services Inc 33.75%$ 33.748 millions
Addus Homecare Corporation33.51%$ 33.509 millions
Halozyme Therapeutics Inc 32.78%$ 32.779 millions
Chemed Corporation31.80%$ 31.799 millions
Intuitive Surgical Inc 29.29%$ 29.289 millions
Gilead Sciences Inc 21.61%$ 21.613 millions
Neurocrine Biosciences Inc 21.31%$ 21.314 millions
Docgo Inc 20.50%$ 20.505 millions
Progyny Inc 20.34%$ 20.339 millions
Bristol myers Squibb Company20.27%$ 20.274 millions
Dexcom Inc 19.27%$ 19.269 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com